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ABSTRACT
The synthetic curcumin analog B5 is a potent inhibitor of thioredoxin reductase 
(TrxR) that has potential anticancer effects. The molecular mechanism underlying 
B5 as an anticancer agent is not yet fully understood. In this study, we report that 
B5 induces apoptosis in two human cervical cancer cell lines, CaSki and SiHa, as 
evidenced by the downregulation of XIAP, activation of caspases and cleavage of 
PARP. The involvement of the mitochondrial pathway in B5-induced apoptosis was 
suggested by the dissipation of mitochondrial membrane potential and increased 
expression of pro-apoptotic Bcl-2 family proteins. In B5-treated cells, TrxR activity 
was markedly inhibited with concomitant accumulation of oxidized thioredoxin, 
increased formation of reactive oxygen species (ROS), and activation of ASK1 and 
its downstream regulatory target p38/JNK. B5-induced apoptosis was significantly 
inhibited in the presence of N-acetyl-l-cysteine. Microscopic examination of B5-treated 
cells revealed increased presence of cytoplasmic vacuoles. The ability of B5 to activate 
autophagy in cells was subsequently confirmed by cell staining with acridine orange, 
accumulation of LC3-II, and measurement of autophagic flux. Unlike B5-induced 
apoptosis, autophagy induced by B5 is not ROS-mediated but a role for the AKT and 
AMPK signaling pathways is implied. In SiHa cells but not CaSki cells, B5-induced 
apoptosis was promoted by autophagy. These data suggest that the anticarcinogenic 
effects of B5 is mediated by complex interplay between cellular mechanisms governing 
redox homeostasis, apoptosis and autophagy.
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INTRODUCTION
The thioredoxin (Trx) system, composed of 
thioredoxin reductase (TrxR), Trx, and NADPH, is a major 
cellular redox control mechanism that is often deregulated 
in malignancy [1]. The Trx system has special significance 
in tumor biology as tumor cells are often subject to 
oxidative stress arising from the tumor environment [2] and 
increased consumption of reducing equivalents to support 
DNA synthesis [3, 4]. The Trx system may be involved 
in carcinogenesis in several ways. Firstly, it can promote 
cancer cell proliferation through its modulatory effect on 
redox-regulated transcription factors and/or protein kinase 
signaling cascades [5]. Secondly, the Trx system is needed 
for the activity of peroxiredoxins [6], which are ubiquitously 
expressed antioxidant enzymes that scavenge reactive 
oxygen species (ROS) [7, 8] and the direct inhibition of 
apoptosis signal-regulating kinase 1 (ASK1) [9], a mitogen-
activated protein kinase (MAPK) kinase kinase (MAPKKK) 
that activates the p38 and JNK MAPK pathways. As a 
result, tumor cells usually have higher resistance against 
oxidative stress-induced apoptosis [10]. Thirdly, the Trx 
system has also been implicated in tumor angiogenesis [11] 
through the induction of hypoxia-inducible factor 1 (HIF-1) 
and vascular endothelial growth factor (VEGF) [12], and 
the Trx-dependentheme oxygenase-1 (HO-1) pathway 
[13]. Fourthly, high levels of Trx expression are associated 
with tumor invasion and metastasis. Thus, Trx promotes 
matrix metalloproteinase activity and stimulates cancer 
cell invasion [14]. Trx over expression is linked to tumor 
metastasis [15] and is implicated in malignant potential 
of tumor cells [1]. Indeed, Trx levels are upregulated in 
the plasma of cancerpatients [16] and a high Trx level is 
often correlated with cancer resistance to chemotherapeutic 
agents [17–20]. Thus, the Trx system may represent an 
important therapeutic target in cancer treatment.
TrxR is a ubiquitously expressed selenocysteine 
(Sec)-containing oxidoreductase that catalyzes the 
NADPH-dependent reduction of Trx [21]. In our previous 
study, B5 as one of the synthetic curcumin analogs with 
structure shown in Figure 1A was found to potently inhibit 
TrxR by covalent modification of Cys497 and Sec498 
[22]. However, the potential anticancer effects of B5 have 
not been examined. The aim of the present study was to 
investigate the mechanisms of action of this TrxR inhibitor 
in two human cervical cancer cell lines CaSki and SiHa.
RESULTS
Effects of B5 on the growth of CaSki and 
SiHa cells
The effect of B5 and on cellular viability in 
comparison to curcumin was examined in the Caski and 
SiHa human cervical cancer cells. In MTT assay, the IC50 
values of B5 and curcumin were respectively 6.1 and 
28.3 μM in CaSki cells. In SiHa cells, the IC50 values were 
5.3 and 18.5 μM, respectively (Fig. 1B). These results 
show that B5 is relatively more cytotoxic towards cancer 
cells than natural curcumin.
B5 induces cell cycle arrest and apoptosis in 
CaSki and SiHa cells
To study the mechanism underlying the inhibitory 
effects of B5 on cancer cell growth, cell-cycle analysis was 
performed for B5-treated CaSki and SiHa cells by flow 
cytometry. The treatment of cells with B5 (16 μM) resulted 
in an increase in the percentage of cells in the G2/M phases 
by18% and 10% respectively in the CaSki and SiHa cells 
when compared to the controls. A similar increase in the 
percentage of G2/M cells was again observed after treating 
the cells with B5 at 32 μM (Fig. 2A).
Whether the treatment of cells with B5 would also 
result in apoptosis was next examined. Cells were stained 
with a mixture of Annexin-V-FITC/PI followed by flow 
cytometry analysis. B5 at 16 and 32 μM caused readily 
detectable cell death to occur in both cell lines as evident 
by the presence of cells stained positively with Annexin 
V-FITC only (early apoptotic) or Annexin-V-FITC/PI (late 
apopotic). In the CaSki cells, B5 at 16 and 32 μM caused 
a small but distinct increase in the percentage of early 
apoptotic cells. By contrast, a rather large increase in the 
percentage of late apoptotic cells amounting to 58.7% and 
60.5% respectively at 16 and 32 μM of B5 was observed. 
Similarly, more late than early apoptotic cells were 
formed in B5-treated SiHa cells. At B5 concentrations 
of 16 and 32 μM, the percentage late apoptotic cells was 
approximately double that of the untreated control.
We next analyzed the effect of B5 on the activation 
of caspases and expression of XIAP. Western blotting 
analysis showed that B5 induced the activation of 
caspase 3, caspase 8, and caspase 9. Consistent with the 
activation of caspases, the caspase 3 substrate PARP was 
found to undergo specific proteolytic cleavage as suggested 
by the presence of the 116 kDa to 89 kDa fragment in 
cells treated with B5 at 4, 16 and 32 μM in CaSki cells. 
In the case for SiHa cells, an increase in the abundance 
of the 89 kDa PARP fragment could readily be seen in 
cells treated with B5 at 32 μM (Fig. 2C). In addition, B5 
treatment downregulated the expression of XIAP (Fig. 2C), 
which is considered the most potent human IAP protein 
currently identified because it inhibits the activity of both 
caspase 3 and caspase 9 [23, 24]. These results suggest that 
caspases activation may underlie the apoptotic activity of 
B5 in cervical cancer cells.
B5 induces mitochondrial dysfunction and 
regulates the expression of Bcl-2 family proteins
A distinctive feature of the early phase apoptosis is 
a change in mitochondrial membrane potential (Δψm) [25] 
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that is an important parameter of mitochondrial function. 
The Δψm is an early event preceding caspase activation, 
and is regarded as a hallmark of apoptosis [26]. 
Therefore, we measured Δψm in B5-treated CaSki and 
SiHa cells using the membrane-permeable JC-1 dye. In 
apoptotic or unhealthy cells with low Δψm, JC-1 remains 
in the monomeric form, which has green fluorescence 
[27]. As shown in Fig. 3B, a marked increase in JC-1-
related green fluorescence can be seen in both the CaSki 
and SiHa cells treated with 16 or 32 μM of B5. These 
results demonstrate that B5 induced MMP disruption in 
both cell lines.
Mitochondrion-mediated intrinsic apoptotic 
pathway occurs in response to various stimuli, including 
oxidative stress, and is regulated by the proteins of 
the Bcl-2 family [28, 29]. In this study, we found that 
B5 induced downregulation of antiapoptotic Bcl-xL, 
upregulation of proapoptotic Bid/Bok, and activation 
of Bim cleavage in CaSki cells (Fig. 3A). However, 
the expression of Bax and Bcl-2 was not affected by 
B5 (data not shown). These results indicate that B5 
induces apoptosis of cancer cells through induction of 
mitochondrial dysfunction caused by deregulation of 
Bcl-2 family proteins.
Effect of B5 on ROS generation
ROS have important roles in intracellular signal 
transduction and redox homeostasis [30]. However, 
excessive ROS accumulation can exert toxic effects 
and cause oxidative stress, damaging main cellular 
components such as DNA, lipids, and proteins [31] 
and causing apoptosis [32]. To investigate whether 
B5-induced apoptosis was related to the changes 
in intracellular redox environment, we examined 
intracellular ROS production in B5-treated cervical 
cancer cells using DCFH-DA. As shown in Fig. 4A, 
B5 caused ROS accumulation in CaSki and SiHa cells, 
especially after the treatment for 3 and 2 h, respectively. 
The pre-treatment of NAC, a ROS scavenger, reduced 
B5-induced apoptosis by 10.5% and 13.4%, respectively 
(Fig. 4B). Together, these results suggest that ROS 
accumulation plays an important role in B5-induced cell 
apoptosis.
Figure 1: Effects of B5 and curcumin on cell growth. A. Chemical structure of B5. B. Effects of B5 and curcumin on cell growth. 
CaSki and SiHa cells were treated with the indicated concentrations of B5 or curcumin for 48 h; cell viability was quantified by the MTT 
assay. Data are the mean ± SD of at least three independent experiments.
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Figure 2: B5 induced apoptosis and cell cycle arrest in CaSki and SiHa cells. A. Effects of B5 on cell cycle distribution. Cells 
were treated with 0, 4, 16, and 32 μM B5 for 48 h, fixed in 70% ethanol, stained with PI, and cell cycle distribution was assessed by flow 
cytometry. The percentage of cells in each cell cycle phase is indicated as the mean ± SD of three independent experiments. B. Induction of 
apoptosis by B5 in CaSki and SiHa cells. Cells were treated as above and analyzed by flow cytometry after Annexin-V-FITC/PI staining; 
data are presented as the mean ± SD of three independent experiments. *P < 0.5 and **P < 0.01. C. Western blotting analysis of the 
expression of the following: pro- and cleaved-caspases 3, 8, and 9; PARP (86kDa); and XIAP. Data are representatives of three independent 
experiments.
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Effect of B5 on the Trx system
We next examined B5 effects on the Trx system. 
SC-TrxR assay showed that B5 inhibited TrxR activity 
dose-dependently in both cell lines (Fig. 5A). Interestingly, 
the expression level of Trx was increased in both cell lines, 
whereas that of TrxR was increased in SiHa cells but 
decreased in CaSki cells (Fig. 5B). This result was further 
verified by the RT-PCR assay: B5 upregulated Trx mRNA 
in both cell lines, while TrxR mRNA was upregulated only 
in SiHa cells (Fig. 5C). Nevertheless, the oxidized Trx 
form was increased while the reduced form was decreased 
dose-dependently in both cell lines after the treatment 
with B5 (Fig. 5D). Together, these results indicate that B5 
deregulates the Trx system in cancer cells.
Effect of B5 treatment on the MAPK signaling in 
cervical cancer cells
The inhibition of TrxR activity should result in the 
shift of Trx redox state to the oxidized form (Fig. 5C) 
and dissociation of ASK1 from the complex with 
Trx [10]. In our study, co-immunoprecipitation assay 
showed that B5 induced the release of ASK1 from the 
complex with Trx (Fig. 6A). The increased presence 
of free ASK1 was also indicated by the activation of 
downstream MAPK signaling pathways mediated by 
ASK1: the phosphorylation level of p38 and JNK MAPKs 
notably increased in a time-dependent manner (Fig. 6B), 
suggesting activation of these kinases in CaSki and SiHa 
cells after B5 treatment.
B5 induces autophagy in cervical cancer cells
It is unclear whether autophagy in dying cells is the 
cause of cell death or is actually an attempt to prevent it. 
Autophagy-related cell death has been defined as a form 
of programmed cell death [33]. The treatment with 16 μM 
B5 for 48 h induced autophagy in CaSki and SiHa cells, 
as demonstrated by the presence of autophagic vacuoles 
by electron microscopy (Fig. 7A). To confirm B5-induced 
autophagy, acridine orange, a lysosome marker dye, 
was used to stain CaSki and SiHa cells [34]. As shown 
in Fig. 7B, B5 induced the accumulation of acridine 
orange in cytoplasm of CaSki and SiHa cells, while less 
accumulation of acridine orange was observed in control 
Figure 3: Effects of B5 on the Bcl-2 family proteins and mitochondrial membrane potential (MMP). A. Expression of the 
Bcl-2 proteins was analyzed by western blotting, with GAPDH used as the internal control. B. Flow cytometry analysis of MMP by JC-1 
staining. Cells were treated with 0, 4, 16, and 32 μM B5 for 48 h and stained with JC-1 for 20 min. Cells with MMP loss were gated. Data 
are presented as the mean ± SD of three independent experiments. *P < 0.5 and **P < 0.01.
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Figure 4: The role of ROS production in B5-induced cell apoptosis. A. B5-induced ROS production in CaSki (left) and SiHa 
(right) cells. Cells were treated with 16 μM B5 for 1–4 h, stained with DCFH-DA for 20 min, and analyzed for fluorescence at 525 nm. 
B. B5-induced CaSki and SiHa cell apoptosis was inhibited by NAC pre-treatment. Cells were pre-treated with 10 mM NAC for 30 min and 
treated with 16 μM B5 for 48 h; then, they were stained with Annexin-V-FITC/PI and analyzed by flow cytometry. All values are presented 
as the mean ± SD of three independent experiments. *P < 0.5 and **P < 0.01.
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cells. Furthermore, B5 also induced accumulation of 
LC3-II (Fig. 7D), a lipidated form of LC3 that is regarded 
as an autophagosomal marker in mammals. To obtain 
further confirmation of autophagy, autophagic flux was 
measured in terms of alteration of LC3-II and SQSTM1/
p62 levels in the presence and absence of specific 
lysosomal inhibitors BAF and CQ that act to prevent 
autophagosomal lysosome degradation [35]. As shown in 
Fig. 7D, BAF or CQ treatment resulted in accumulation 
of LC3-II and SQSTM1/p62 both in CaSki and SiHa 
cells. The accumulation of LC3-II was increased and that 
of SQSTM1/p62 was decreased with the combination of 
inhibitors with B5. These results suggest that B5 induces 
autophagy in cervical cancer cells.
The AKT-mediated signaling cascade is one of 
the main signaling pathways regulating autophagy 
[36]. Figure 8A showed that the phosphorylation level 
of AKT was declined after B5 treatment, suggesting 
the involvement of the AKT signaling in B5-induced 
autophagy. The energy sensor AMPK has recently 
been connected to autophagy [37]. Interestingly, the 
phosphorylation level of AMPK was promoted in 
SiHa cells, but it was suppressed in CaSki cells with 
B5 treatment (Fig. 8A). A complex role of AMPK in 
B5-mediated autophagy in cervical cancer cell lines is 
implied. TORC1 is a downstream regulatory target of 
AKT and AMPK and it usually acts as an autophagy-
suppressive regulator. TORC1 activity can be followed by 
the phosphorylation of its substrate 4E-BP1 [35, 38]. As 
shown in Fig. 8A, the phosphorylation level of 4E-BP1 
was decreased in both cell lines upon treatment with B5.
A growing amount of evidences in recent years 
demonstrate that ROS represent important mediators 
of autophagy [39]. To investigate the role of ROS 
in B5-inducd autophagy, CaSki and SiHa cells were 
pretreated with NAC prior to B5 treatment. As shown in 
Fig. 8B, LC3-II accumulation was not affected by NAC, 
suggesting that B5-mediated autophagy induction was 
independent on B5-caused ROS production in cervical 
cancer cells.
Figure 5: Effects of B5 on the Trx system. Cells were treated with 0, 4, 16 and 32 μM B5 for 48 h. A. TrxR activity in cell lysates 
was determined by SC-TrxR assay. Data were presented as the percentage of control. B. Trx and TrxR protein levels were analyzed by SDS-
PAGE and western blotting. C. The mRNA levels of Trx and TrxR were measured by RT-PCR; GAPDH was used as an internal control. 
D. Trx redox status was determined by non-reduced SDS-PAGE and western blotting analysis; GAPDH was used as the internal control. 
All data are representatives of three independent experiments.
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Effect of B5-induced autophagy on B5-triggered 
apoptosis in cervical cancer cells
To explore whether B5-induced autophagy had 
a protective or detrimental effect, CaSki and SiHa 
cells were pre-cultured with two different autophagy 
inhibitors, 3-MA and CQ, respectively, before the 
treatment of B5. The MTT assay indicated that 3-MA, 
a commonly used inhibitor of starvation or rapamycin-
induced autophagy [40], prevented the inhibitory effect 
of B5 on the growth of SiHa cell lines (Fig. 9A right), 
suggesting that B5-induced autophagy may have an 
apoptosis-promoting effect. To verify this hypothesis, 
flow cytometry was used to analyze cellular apoptosis 
induced by the combination of B5 and 3-MA. The 
results indicate that B5-induced autophagy indeed had 
an apoptosis-promoting effect but only in SiHa cells 
(Fig. 9B bottom).
It has been reported that 3-MA might also inhibit 
PI3K and can thus promote autophagy in some systems 
as well as affect cell survival [41]. Another autophagy 
inhibitor CQ was therefore used to further examine the 
involvement of autophagy in B5-triggered apoptosis by 
MTT assay and flow cytometry analysis. As shown in 
Fig. 9C and 9D, CQ prevented the growth inhibitory effect 
of B5 and attenuated B5-triggered apoptosis in SiHa cells. 
However, no obvious changes of growth and apoptosis 
were observed in CaSki cells when B5 was combined 
Figure 6: Effects of B5 on ASK1 and p38/JNK MAPKs. A. CaSki and SiHa cells were treated with 16 μM B5 for 8h; ASK1-
Trx complex was precipitated using Protein A beads and analyzed by western blotting with ASK1 and Trx antibodies. B. Activation of  
p38/JNK MAPKs. Cells were treated with 16 μM B5 for 0, 6, 12 and 24 h and subjected to western blotting analysis; GAPDH was used as 
the internal control.
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Figure 7: B5-induced autophagy in CaSki and SiHa cells. A. Ultrastructure of CaSki and SiHa cells with the treatment of 16 μM 
B5 for 48 h; transmission electron microscopy shows multiple autophagic vacuoles. B. Cells were treated with B5 for 48 h and then 
stained with acridine orange and examined under a fluorescence microscope at magnification of 400. C. Western blotting analysis of LC3 
expression in CaSki and SiHa cells with the treatment of 0, 4, 16, and 32 μM B5 for 48 h. D. Autophagic flux analysis by measuring the 
expression levels of SQSTM1/p62 or LC3-II. CaSki and SiHa cells were treated with BAF or CQ prior to 16 μM B5 treatment for 48 h. 
Expression levels of SQSTM1/p62 and LC3-II were determined by western blotting analysis.
Figure 8: A. Expression levels of p-AKT, AKT, p-4E-BP1, AMPK and p-AMPK in CaSki and SiHa cells. Cells were 
treated with 0, 4, 16, and 32 μM B5 for 48 h and subjected to western blotting analysis. GAPDH was used as the internal control. B. Effect 
of ROS on B5-inducd autophagy. CaSki and SiHa cells were treated with ROS inhibitor NAC prior to 16 μM B5 treatment for 48 h. 
Expression levels of LC3-II were determined by western blotting analysis. All data are representatives of three independent experiments.
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Figure 9: Effects of the autophagy inhibitors, 3-MA and CQ, on B5-induced cell growth inhibition and apoptosis. The 
cells were pretreated with 5 mM 3-MA A. and B.
(Continued )
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Figure 9: (continued ) C. and D. For 1 h and then treated with 16 μM B5 for 48 h. Cell viability was determined by the MTT assay 
(A and C). Apoptotic cells were quantified by Annexin V-FITC/PI staining analysis (B and D). Data are presented as the mean ± SD of three 
independent experiments. *P < 0.5 and **P < 0.01.
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with CQ. These results suggest that B5-induced autophagy 
has different roles in B5-induced apoptosis in CaSki and 
SiHa  cells.
DISCUSSION
The mammalian TrxR is a Sec-containing 
oxidoreductase that has been established as an anticancer 
drug target [4, 42, 43] because of its role as a key player 
in cell death program [44]. The highly reactive Sec active 
site with low pKa value and easily accessible location 
makes this enzyme a suitable target for drug development. 
In the past decades, many therapeutically used synthetic 
and natural compounds with TrxR inhibitory activity 
have been found to exhibit anticancer potential [45]. 
Among them, gold compounds [46], platinum drugs [47], 
flavonoids [48], quinines [49], mercury [50], arsenic 
trioxide [51], curcumin [52] and its analogs [22] have been 
tested as novel cancer treatments or adjuncts to existing 
therapy; some of them have shown potent therapeutic 
effects [53]. In the present study, we demonstrated that 
B5, a newly synthesized TrxR inhibitor and a curcumin 
analog, exhibited significant antitumor activity based 
on the modulation of the intracellular redox status and 
autophagy (Fig. 10).
Mitochondria plays a very important role as the 
intrinsic apoptosis pathway [54]. The key event of 
mitochondrion-induced apoptosis is the permeabilization 
of the OMM, which occurs in response to various stimuli 
and is mainly regulated by the members of the Bcl-2 
family [28, 29]. Indeed, we found that B5 decreased Δψm 
in CaSki and SiHa cells (Fig. 3B) and downregulated the 
expression of antiapoptotic Bcl-xL while upregulating that 
of proapoptotic Bid/Bok (Fig. 3A), indicating that the loss 
of Δψm plays an important role in B5-induced apoptosis in 
cervical cancer cells.
MMP loss is an early event preceding caspase 
activation, which causes the leakage of small molecules, 
such as cytochrome c and second mitochondria-derived 
activator of caspases (Smac), from the mitochondria 
into the cytoplasm [55], followed by the (a) recruitment 
of apoptotic protease activating factor-1 (Apaf-1) and 
procaspase9 to form the apoptosome [56], (b) activation 
of caspase 9 and caspase 3, and (c) execution of apoptosis 
[57]. The inhibitor of apoptosis (IAP) family negatively 
regulates this process, and the most potent human IAP 
protein XIAP inhibits the activity of both caspase 9 and 
caspase 3 [58]. Our data demonstrate that B5 induced 
the activation of caspases 3, 8, and 9 in CaSki and SiHa 
cells (Fig. 2C) and downregulated the expression of XIAP 
(Fig. 2C), indicating that B5 induced apoptosis in cancer 
cells through the intrinsic as well as extrinsic apoptotic 
pathways as evidenced by the activation of caspase 8 [43].
The inhibition of TrxR activity results in the 
accumulation of ROS. In healthy cells, ROS are natural 
byproducts of metabolism and have important roles in 
cell signaling and homeostasis. However, excessive 
ROS generation can damage cell structures and cause 
oxidative stress and cell death [31]. In our experiments, 
B5 induced time-dependent ROS accumulation (Fig. 4A) 
suppression in TrxR activity and increase in the oxidized 
Trx form (Fig. 5A and 5D) in cancer cells; furthermore, 
the ROS scavenger NAC reduced B5-elicited apoptosis 
(Fig. 4B), suggesting that B5-dependent disruption of the 
Trx system and excessive ROS accumulation underlie 
the proapoptotic activity of B5. It should be noted that a 
decrease of ROS level was observed in CaSki and SiHa 
cells after the treatment of B5 for 4 and 3 h, respectively. 
It may be that some cellular antioxidant proteins, such 
as peroxiredoxins, glutathione peroxidase, and catalase, 
participated in preventing the buildup of intracellular 
ROS [59].
MAPK signaling pathways are closely involved 
in the response to oxidative stress [60]. JNK and p38 
MAPKs play important roles in regulating H2O2-induced 
cell death and are critical mediators of oxidative stress-
induced apoptosis [61, 62]. The binding of reduced Trx 
to the upstream kinase ASK1 can block JNK and p38 
activity; however, when Trx is oxidized, the complex 
dissociates and the released ASK1 activates the JNK and 
p38 pathways, thereby promoting apoptosis. Our results 
show that B5 treatment causes ASK1 dissociation from the 
complex with Trx in SiHa cells (Fig. 6A) and activation of 
JNK and p38 MAPKs (Fig. 6B), suggesting that MAPK 
pathway may be involved in B5-induced apoptosis. The 
more detailed role of MAPK pathway in B5-induced 
apoptosis and the relationship between B5-mediated ROS 
production and MAPKs signal transduction are worthy of 
further investigation.
Although autophagy can be upregulated in many 
tumor cells under stress conditions such as chemotherapy 
or nutrient deficiency, the exact role of autophagy in 
cancer cell death is still not clear [63, 64]. After short-term 
stressful effects, autophagy activation generally facilitates 
the restoration of cell homeostasis and survival. However, 
under permanent adverse conditions, autophagy is induced 
to promote elimination of damaged cells by apoptosis [33]. 
Here, we investigated the association between apoptosis 
and autophagy in cervical cancer cells treated with the 
combination of B5 and the autophagy inhibitors. The 
reduction in autophagy relieved B5 inhibitory effect on 
cell growth (Fig. 9A and 9C), which is verified by Annexin 
V-FITC/PI staining analysis in SiHa cells (Fig. 9B and 9D), 
suggesting a crosstalk between B5-induced apoptosis 
and autophagy in SiHa cells. However, the treatment of 
autophagy inhibitors, both 3-MA and CQ, had no effect on 
B5-induced apoptosis in CaSki cells (Fig. 9), suggesting 
different signaling pathways may be involved in 
B5-mediated autophagy in CaSki and SiHa cell lines.
Indeed, in this study, we found that AKT signaling, 
one of the main signaling pathways regulating autophagy, 
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was inconsistently inhibited in CaSki and SiHa cells 
(Fig. 8A). Although the phosphorylation level of AKT 
was inhibited markedly at high concentration (32 μM) 
of B5 in both cell lines, it was hardly reduced by 16 
μM B5 in SiHa cells in spite of autophagy induction 
under the treatment of this concentration, indicating the 
involvement of some other pathway(s) in the regulation of 
B5-induced autophagy in SiHa cells. Herein AMPK was 
found to one of the possible regulators. There is mouting 
evidence that AMPK activates autophagy through 
inactivation of TORC1 and direct phosphorylation of 
the protein kinase ULK1 [37]. Our results in Figure 8A 
that the phosphorylation level of AMPK was elevated 
dramatically by B5 in SiHa cells suggests that B5 may 
induce autophagy in SiHa cells through coordinated 
regulation of AKT and AMPK followed by the 
suppression of TORC1, whose activity was monitored by 
the decreased phosphorylation level of 4E-BP1 (Fig. 8A), 
a substrate of TORC1. It is interesting to note that some 
unexpected result was observed in CaSki cells, namely 
the level of phosphorylated AMPK was decreased, which 
was inconsistent with that of SiHa cells. It may be that 
more complex network of regulation are involved in B5-
mediated autophagy in CaSki cells since the activation of 
AMPK crucially depends on phosphorylation by multiple 
upstream kinases, like LKB1, CaMKK, TAK1, etc [65]. 
The detailed roles of the regulation network in B5-
mediatd autophagy and crosstalks and feedbacks between 
B5-induced apoptosis and autophagy remain to be further 
explored.
In summary, we demonstrated that B5 activated 
apoptosis in cervical cancer cells via suppression of 
Trx system and functional disruption of mitochondria. 
The accumulation of the oxidized Trx would cause ROS 
accumulation and affect a number of Trx-dependent 
pathways, including those of ASK1, JNK and p38 
MAPKs, which may contribute to B5-induced apoptosis. 
B5 also promoted apoptosis by induction of autophagy, 
which might involve the inhibition of the Akt signaling 
and was independent of ROS (Fig. 10). Our results 
show that B5 is a more efficient anticancer agent 
than curcumin in vitro and warrants further in vivo 
investigation. Our data provide important information 
for the explanation of the anticancer activity of 
curcumin analogs and for the development of new 
curcumin analogs targeting TrxR with high activity 
against cancer cells.
MATERIALS AND METHODS
Cell culture and reagents
The human cervical cancer cell lines CaSki and 
SiHa were purchased from the Cell Bank of the Chinese 
Academy of Sciences (Shanghai, China) and stored in 
liquid nitrogen. Cells were cultured in DMEM (Gibco, 
USA) containing 10% fetal bovine serum (FBS, Gibco, 
USA), 100 U/mL penicillin, and 100 μg/ml streptomycin 
(complete medium) at 37°C in a humidified 5% CO2 
atmosphere.
Curcumin was isolated from Curcuma longa 
roots and purified by silica gel chromatography. B5 was 
synthesized in our laboratory as described in a previous 
report [66].
Dimethylsulfoxide (DMSO), 3-methyladenine 
autophagy inhibitor (3-MA), 5, 5′, 6, 6′-tetrachloro-1, 1′, 3, 
3′-tetraethyl-imidacarbocyanine iodide (JC-1), N-acetyl-
l-cysteine (NAC), 2′, 7′-dichlorofluoresceindiacetate 
(DCFH-DA), selenocystine (SC), acridine orange, 
chloroquine (CQ), bafilomycin A1 (BAF), and 3-(4, 
5-dimetrylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT) were purchased from Sigma (St. Louis, 
MO, USA). Propidium iodide (PI), RNase and RIAP 
buffer kit containing protease inhibitors cocktail 
(phenylmethanesulfonyl fluorideand and leupeptin) and 
phosphatase inhibitors cocktail (sodium fluoride and 
sodium orthovanadate) were purchased from Beyotime 
(Shanghai, China).
Antibodies against the following were purchased 
from Cell Signaling Technology (Beverly, MA, USA): 
ASK1; GAPDH; Bax; caspases 3, 8, and 9; X-linked 
inhibitor of apoptosis (XIAP); PARP; p38; p-p38 
MAPK (Thr180/Tyr182); AKT; p-AKT (Ser473); JNK; 
p-JNK1/2 (Thr183/Tyr185); p-4E-BP1; LC3; AMPK; 
p-AMPK and SQSTM1/p62. Trx1, TrxR and horseradish 
peroxidase-conjugated secondary antibodies were 
purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA).
Growth inhibition assay
Growth inhibition of cancer cells by B5 was 
measured by the MTT assay. Exponentially grown 
CaSki and SiHa cells were seeded in 96-well plates at the 
density of 5 × 103 cells per well in complete medium and 
allowed to attach for about 12 h. Cells were then treated 
with a range of B5 concentrations for 48h. The medium 
was removed, and 50 μl of the same medium containing 
5 mg/ml MTT was added to each well for another 4 h. 
After medium removal, 100 μl DMSO was added to 
each well for 10 min. Cell viability was assessed by the 
absorbance at 570 nm and measured using a microplate 
reader (BIO-RAD, USA); IC50 values of B5 for each 
cell line were determined by comparison with untreated 
control cells.
Flow cytometry analysis of cell cycle arrest 
and apoptosis
CaSki and SiHa cells (2 × 105) were seeded in 
60-mm Petri dishes at 1 day before the experiment. 
For cell cycle analysis, cells were harvested, washed 
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twice with ice-cold PBS, and fixed in 70% ethanol at 
4°C overnight after treatment with 4, 16, and 32 μM 
B5 for 48 h. Then cells were washed once with ice-
cold PBS and re-suspended in 1 mL of staining reagent 
containing 50 mg/mL PI and 100 mg/mL RNase for 
30 min in the dark. To assess apoptosis, harvested 
cells were washed twice with ice-cold PBS, and 
stained with Annexin-V-FITC/PI (KeyGEN, Nanjing, 
China) according to the manufacturer’s instructions. 
Cell cycle arrest and apoptosis were analyzed by flow 
cytometry (BD FACSCalibur, USA). Fluorescence of 
Annexin-V-FITC and PI was monitored at 630 nm and 
525 nm, respectively.
Evaluation of mitochondrial membrane 
potential (MMP)
CaSki and SiHa cells (2 × 105) were seeded in 
60-mm Petri dishes at 1 day before the experiment. After 
the treatment with 4, 16, and 32 μM B5 for 48 h, cells were 
harvested, washed twice with ice-cold PBS, and incubated 
with JC-1 (10 μg/ml) in the dark for 15 min at 37°C. Cells 
Figure 10: TrxR inhibitor B5-mediated intracellular signaling that led to apoptosis in human cervical cancer cells. Key: 
black arrows, activation; black blocks, inhibition; dashed arrows or blocks, indirect interaction; circled question mark, complex regulation.
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were washed three times with ice-cold PBS and analyzed 
by flow cytometry using emission wavelengths of 590 nm 
and 525 nm.
Determination of ROS production
CaSki and SiHa cells (2 × 105) were seeded in 
60-mm Petri dishes. After the treatment with 16 μM B5 
for 1–4 h, cells were incubated with 10 μM DCFH-DA 
for 15 min in the dark, washed three times with ice-cold 
PBS, and seeded in 96-well NUNC plates (Thermo, USA) 
at the density of 5 × 103 per well; DCFH-DA fluorescence 
was measured at 525 nm using a microplate reader (Tecan 
F500, Switzerland).
Transmission electron microscopy analysis
CaSki and SiHa cells (2 × 105) were seeded in 
60-mm Petri dishes at 1 day before the experiment. 
After the treatment with 16 μM B5 for 48 h, cells were 
harvested, washed twice with ice-cold PBS, resuspended 
in 70% Karnovsky’s fixative, and incubated for 20 min 
at room temperature. Ultrathin slices were prepared and 
examined under Hitachi 7000 transmission electron 
microscope (Tokyo, Japan).
Acridine orange staining
CaSki and SiHa cells were treated as described 
in transmission electron microscopy analysis. After 
harvesting, cells were washed twice with ice-cold PBS 
and incubated with 1 μg/ml acridine orange for 15 min at 
37°C. Subsequently, cells were washed three times with 
ice-cold PBS and then observed under a fluorescence 
microscope (Olympus IX71, Japan).
Immunoblotting and immunoprecipitation
After treatment with different concentrations of 
B5 for 48 h, cells were harvested and washed twice with 
ice-cold PBS. For immunoblotting analysis, cell lysates 
were prepared by incubation in RIPA buffer containing 
protease inhibitors cocktail (1 mM phenylmethanesulfonyl 
fluorideand and 1 μg/ml leupeptin) and phosphatase 
inhibitors cocktail (1 mM sodium fluoride and 1 mM 
sodium orthovanadate) for 30 min on ice and centrifuged 
at 12,000 rpm for 15 min. Supernatants were collected, 
and equal amounts of denatured proteins (heat samples to 
95°C for 5 min) were resolved in SDS-PAGE gels. Proteins 
were transferred to nitrocellulose membranes, blocked 
with 5% nonfat milk at room temperature for 1 h, and 
incubated with primary antibodies overnight at 4°C. The 
membranes were washed three times with Tris-buffered 
saline-5% Tween 20 (TBST) solution and incubated with 
a horseradish peroxidase-conjugated secondary antibody at 
room temperature for 1 h; protein bands were visualized by 
enhanced chemiluminescence (Millipore, MA, USA) and 
analyzed by densitometry.
For immunoprecipitation, equal amounts (according 
to protein content) of cell lysates prepared as above 
were incubated with Trx1 antibody immobilized on 
protein A magnetic beads (Santa Cruz, CA, USA) at 
4°C overnight. The pellet was washed five times with 
ice-cold NP40 (Beyotime, Shanghai, China); proteins 
were extracted with SDS-loading buffer and analyzed by 
immunoblotting with Trx1 and ASK1 antibodies.
TrxR activity analysis in cells
TrxR activity in cervical cancer cells was determined 
by SC-TrxR assay as described by Cunniff et al [67]. 
Cells were incubated with different concentrations of 
B5 for 48 h. Cells were harvested and cell lysates were 
prepared as described above in the presence of protease 
inhibitors. Protein concentrations of the supernatants 
were determined by Bradford reagent. 25 μg of extract 
was incubated with 1 mM NADPH and 2 mM SC in TE 
buffer (50 mM Tris-HCl and 2 mM EDTA, pH 7.5) in a 
total volume of 100 μl. Samples of protein only, protein 
and NADPH, and protein and SC were used as controls, 
respectively. The reaction mixture was placed into 96-well 
microplates and monitored in 30-s intervals over a 20-min 
time period at 340 nm using a microplate reader (BioRad, 
USA). TrxR activity was expressed as mol NADPH 
consumed/min.
Thioredoxin redox status assay
After the treatment with 4, 16, and 32 μM B5 for 
48 h, 1 × 106 CaSki and SiHa cells were lysed in 50 mM 
Tris/HCl, pH 8.3, 3 mM EDTA, 6 M guanidinium chloride, 
0.5% Triton X-100 containing 50 mM iodoacetic acid 
[68]. After incubation at 37°C in the dark for 30 minutes, 
excess iodoacetic acid was removed using desalting 
column (Micro Bio-Spin, BIO RAD, USA). Oxidized and 
reduced Trx-1 were separated by non-reduced SDS-PAGE 
and immunoblotting.
Quantitative real-time RT-PCR
CaSki and SiHa cells (2 × 105 cells/well) were 
seeded into 6-well plates. After the treatment with 
4, 16, and 32 μM B5 for 48 h, cells were harvested, 
and total RNA was isolated using PureLink™ Viral 
RNA/DNA Kits (Invitrogen). The quantitative PCR 
of Trx-1 and TrxR1 mRNA was determined using 
SYBR Green Realtime PCR Master Mix (Toyobo) as 
described by the manufacturer. Gene-specific primer 
pairs used in this study were as follows: TrxR sense 
5′-TGTTGAATGAACAACTGTGC-3′ and TrxR antisense 
5′-TCCTCAGCCAGTACATTGAC-3′, Trx sense 5′-CATA 
ACCAGCCATTGGCTATT-3′ and Trx antisense 5′-GCAT 
AATGTTTATTGTCACG-3′, GAPAH sense 5′-CACCCA 
GAAGACTGTGGATGG-3′ and GAPDH antisense 
5′-GTCTACATGGCAACTGTGAGG-3′.
Oncotarget30954www.impactjournals.com/oncotarget
Statistical analysis
All data are reported as mean ± SD of three 
independent experiments performed in triplicate. 
The differences between two treatment groups were 
analyzed by two-tailed unpaired Student’s t test; three 
or more groups were compared by one-way ANOVA 
multiple comparisons. P-values < 0.05 were regarded as 
statistically significant.
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